Patents by Inventor Carolyn A. Fairbanks

Carolyn A. Fairbanks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANALGESIC AND ANTI-ADDICTIVE COMPOSITIONS FOR TREATMENT OF CHRONIC PAIN AND OPIOID ADDICTION
    Publication number: 20220002238
    Abstract: The invention provides a compound of formula I and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the formula I compounds, as well as methods of using such as therapeutic agents for the treatment of pain-related disorders and diseases and in combination with other therapeutic agents.
    Type: Application
    Filed: November 6, 2019
    Publication date: January 6, 2022
    Applicant: Regents of the University of Minnesota
    Inventors: Carolyn A. FAIRBANKS, Herbert T. NAGASAWA, George L. WILCOX, Cristina D. PETERSON, Kelley F. KITTO
  • ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20210346473
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: March 25, 2021
    Publication date: November 11, 2021
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • METHODS TO TREAT POMPE DISEASE USING A RECOMBINANT ADENO-ASSOCIATED VIRUS
    Publication number: 20210085759
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: December 10, 2020
    Publication date: March 25, 2021
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20210085760
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: December 10, 2020
    Publication date: March 25, 2021
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20190298812
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: June 11, 2019
    Publication date: October 3, 2019
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20180271955
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • METHODS TO TREAT POMPE DISEASE USING A RECOMBINANT ADENO-ASSOCIATED VIRUS
    Publication number: 20180271956
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: May 31, 2018
    Publication date: September 27, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • METHODS TO TREAT CEROID LIPOFUSCINOSIS USING A RECOMBINANT ADENO-ASSOCIATED VIRUS
    Publication number: 20180271957
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: May 31, 2018
    Publication date: September 27, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20180264090
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 20, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • METHODS TO TREAT MUCOPOLYSACCHARIDE TYPE II OR DEFICIENCY IN IDURONATE-2-SULFATASE USING A RECOMBINANT ADENO-ASSOCIATED VIRUS ENCODING IDURONATE-2-SULFATASE
    Publication number: 20180099030
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: September 27, 2017
    Publication date: April 12, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20180036388
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: September 27, 2017
    Publication date: February 8, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks
  • Methods to treat mucopolysaccharide type I or deficiency in alpha-L-iduronidase using a recombinant adeno-associated virus encoding alpha-L-iduronidase
    Patent number: 9827295
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: November 28, 2017
    Assignees: Regents of the University of Minnesota, REGENXBIO Inc.
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20160120960
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: May 15, 2014
    Publication date: May 5, 2016
    Applicant: Regents of the University of Minnesota
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • Analgesic composition and method for using same
    Patent number: 6204271
    Abstract: A pharmaceutical analgesic composition comprise an opioid analgesic agent and moxonidine as a non-opioid agent with analgesic activity. Administration of an opioid analgesic agent and moxonidine as a non-opioid agent produces analgesia in the treatment of pain in mammals.
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: March 20, 2001
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Carolyn A. Fairbanks, George L. Wilcox, Laura S. Stone, Kelley F. Kitto
  • Agmatine as a treatment for neuropathic pain
    Patent number: 6150419
    Abstract: A treatment and composition for neuropathic pain by administering an effective amount of agmatine.
    Type: Grant
    Filed: February 10, 2000
    Date of Patent: November 21, 2000
    Inventors: Carolyn A. Fairbanks, George L. Wilcox, Kristin Schreiber, Tinna Marie Laughlin
  • Methods of using moxonidine to inhibit nociceptive pain
    Patent number: 6117879
    Abstract: Moxonidine and its physiologically compatible acid-addition salts are used for the treatment and/or prophylaxis of nociceptive pain, and in particular nociceptive acute and chronic pain.
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: September 12, 2000
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Carolyn A. Fairbanks, George L. Wilcox, Laura S. Stone, Kelley F. Kitto
  • Treatment of neuropathic pain
    Patent number: 6054461
    Abstract: A method of relieving neuropathic pain uses moxonidine and its physiologically compatible acid-addition salts for the treatment and/or prophylaxis of neuropathic pain. A composition comprising an effective amount of moxonidine, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier, is administered to a subject in need of such treatment. The composition may be administered intrathecally.
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: April 25, 2000
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Carolyn A. Fairbanks, George L. Wilcox, Tinna M. Laughin